Echocardiographic and Clinical Outcomes of Central Versus Noncentral Percutaneous Edge-to-Edge Repair of Degenerative Mitral Regurgitation  by Estévez-Loureiro, Rodrigo et al.
Journal of the American College of Cardiology Vol. 62, No. 25, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.05.093Echocardiographic and Clinical Outcomes
of Central Versus Noncentral Percutaneous
Edge-to-Edge Repair of Degenerative
Mitral Regurgitation
Rodrigo Estévez-Loureiro, MD, PHD,* Olaf Franzen, MD,y Reidar Winter, MD, PHD,z
Lars Sondergaard, MDSC,y Per Jacobsen, MD,z Gary Cheung, MD,y Neil Moat, MS,*
Nikolaj Ihlemann, PHD,y Matteo Ghione, MD,* Susanna Price, MD, PHD,* Alison Duncan, MD,*
Tine Streit Rosenberg, RN,y Sarah Barker, MSC,* Carlo Di Mario, MD, PHD,*
Magnus Settergren, MD, PHDz
London, United Kingdom; Copenhagen, Denmark; and Stockholm, SwedenFrom the *N
Unit, Royal
Rigshospital
Department
Stockholm,
has an educ
Dr. Di Ma
a proctor fo
reported tha
disclose. Dr
Manuscri
accepted MaObjectives Tational Institute Health
Brompton Hospital, Lond
et, Copenhagen, Denmar
of Cardiology, Karolinsk
Sweden. Mr. Moat is a c
ational contract with Med
rio has received speaker’
r and on the advisory boa
t they have no relations
s. Estévez-Loureiro and F
pt received February 5, 20
y 14, 2013.his study aimed to assess the clinical and echocardiographic results of MitraClip implantation in noncentral
degenerative mitral regurgitation (dMR) compared with central dMR.Background It is unknown whether the use of MitraClip therapy in noncentral dMR is as safe and effective as in central dMR.Methods We analyzed a multicenter registry of 173 patients treated with the MitraClip and compared results of central and
noncentral dMR.Results Seventy-nine patients (age 79.2  8.0 years, 58.2% men) had dMR. Forty-nine patients (62%) had central dMR, with
the remainder classiﬁed as noncentral dMR (n¼ 30, 38%). Patients with noncentral dMR had a wider pre-procedural
vena contracta (8.5  2.0 mm vs. 6.9  2.2 mm, p ¼ 0.039) and higher systolic pulmonary pressure (57.9  18.0
vs. 47.3  13.0 mm Hg, p ¼ 0.019). Procedural success was the same in both groups (95.5% central vs. 96.7%
noncentral, p ¼ 0.866). Post-procedural MR and New York Heart Association (NYHA) functional class at 1 month
(MR 2, 96.0% vs. 96.6%, p ¼ 0.866, and NYHA functional class II, 81.6% vs. 90.0%, p ¼ 0.335) and 6 months
(95.2% central vs. 91.7% noncentral, p ¼ 0.679; and NYHA functional class >II, 21.1% vs. 0%, p ¼ 0.128) did not
differ between groups. There were also no differences in serious post-procedural adverse events: partial clip
detachment (central n ¼ 1 [2.0%] vs. noncentral n ¼ 1 [3.3%], p ¼ 1.000), death (5.4% central vs. 13.0%
noncentral, p ¼ 0.298), or heart failure admission (10.8% central vs. 8.7% noncentral, p ¼ 0.791).Conclusions In experienced centers, MitraClip treatment can be performed safely and effectively in both central and
noncentral dMR. (J Am Coll Cardiol 2013;62:2370–7) ª 2013 by the American College of Cardiology FoundationSevere mitral regurgitation (MR) is associated with
a signiﬁcant increase in morbidity and mortality (1–4).
Mitral valve (MV) surgery is the standard of treatment for
symptomatic patients with degenerative MR (dMR) (5).Research Cardiovascular Biomedical Research
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13; revised manuscript received April 21, 2013,However, nearly one-half of patients (6,7) referred for
surgery are not operated on, predominantly due to
comorbidities, left ventricular (LV) dysfunction, or age (8).
In these cases, catheter-based interventions have been
proposed as an alternative treatment strategy. The Mitra-
Clip system (Abbott Vascular, Menlo Park, California) isSee page 2378such a therapy, which mimics surgical edge-to-edge MV
repair (9–11). The EVEREST II (Endovascular Valve
Edge-to-Edge Repair II) trial showed that the MitraClip
device is less effective than surgery but safer. Only selected
patients with central MR were included. Successful use of
the device in a more diverse patient population with
Abbreviations
and Acronyms
2D = 2-dimensional
3D = 3-dimensional
dMR = degenerative mitral
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2371complex pathologies has been reported recently (12–14).
However, little is known regarding applicability of the
procedure in noncentral dMR.
The aim of this study was to compare short-term and mid-
term safety and efﬁcacy of MitraClip treatment between
patients with central versus noncentral dMR.regurgitation
LV = left ventricular
MR = mitral regurgitation
MV = mitral valve
NYHA = New York Heart
Association
TEE = transesophageal
echocardiographyMethods
Study design. Between August 2009 and November 2012,
173 patients were treated with the MitraClip device at the
three centers: Royal Brompton Hospital (United Kingdom),
Rigshospitalet (Denmark), and Karolinska University
Hospital (Sweden). The current study involved a retrospective
analysis according to pre-deﬁned inclusion and exclusion
criteria of all patients with dMR. The indication for the
MitraClip was agreed upon by a multidisciplinary team-
comprising cardiologists, cardiac imaging experts, cardiac
surgeons, and anesthetists. Inclusion criteria were severe
dMR, and a predicted clinical beneﬁt of MR reduction in
patients judged to be a high surgical risk. Exclusion criteria
were absent secondary chordal support of the prolapsing
segment, ﬂail gap >20 mm, active endocarditis, intracardiac
thrombus, mitral stenosis, or anatomy unsuitable for septal
puncture, device steering, or device placement.
Before intervention in all patients, transthoracic and trans-
esophageal echocardiography (TEE) were performed and
New York Heart Association (NYHA) functional class was
assessed. During the procedure, the MV was examinedFigure 1 Adjustment and Assessment of Perpendicularity of the Mit
(A) Adjustment and assessment of perpendicularity of the MitraClip using real-time 3-dim
central part of the line of coaptation. (B) Grasping of both leaﬂets in a standard 2-dimensio
mitral valve after MitraClip insertion in the central part of the coaptation line (asterisk den
real-time 3D-TEE, with the clip positioned towards medial commissure. (E) Leaﬂet inserti
catheter and closed to 60 in a noncentral position (asterisk denotes clip). (F) Example o
aspect of the valve (P3, asterisk denotes clip).with 2-dimensional (2D)- and
3-dimensional (3D)-TEE. Clip
entanglement (needed manipula-
tion of the system >120 s) was
deﬁned as a complication. Trans-
thoracic echocardiography was
repeated and NYHA functional
class was reassessed at discharge,
1 month and 6 months. During
follow-up, death from any cause
and hospitalization due to heart
failure were obtained from medi-
cal records.
Echocardiographicmeasurements.
MR severity was assessed by the
individual center at baseline and follow-up using a
comprehensive analysis of quantitative and semiquan-
titative echocardiographic parameters as recommend
(15,16). Systolic pulmonary artery pressure was measured
using the gradient derived from the maximal velocity of
tricuspid regurgitation. Measurement of LV volumes and
ejection fraction was performed according to Simpson’s
biplane method (17). The origin of MR was determined
using the color-compare mode in the 2D transesophageal
commissural and LV outﬂow tract view, as well as the
short-axis view, at the level of the MV. A 3D recon-
struction of the regurgitant jet and MV was used to
conﬁrm the ﬁndings. Central MR (Figs. 1A and 1B) was
considered if the MR originated from the central part ofraClip
ensional transesophageal echocardiography (3D-TEE), with the clip positioned in the
nal left ventricular outﬂow tract view (asterisk denotes clip). (C) Classic double oriﬁce
otes clip). (D) Adjustment and assessment of perpendicularity of the MitraClip using
on controlled in a nonstandard 2-dimensional view with the clip still attached to the
f valve morphology with a single oriﬁce when the MitraClip is implanted in the medial
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2372the line of coaptation (A2–P2) and noncentral MR
(Figs. 1D and 1E) if it originated from the lateral or medial
part of the line of coaptation (A1–P1 and A3–P3).
Procedural success was deﬁned as a reduction in the degree
of MR to 2þ or less.
The procedure. The MitraClip device consists of 2 8-mm
clip arms and opposing grippers, which can be opened and
closed against each other in order to grasp and coapt the
leaﬂets at the origin of the regurgitant jet. The MitraClip
procedure has been described elsewhere (9). Brieﬂy, with the
patient under general anesthesia, and by using ﬂuoroscopic
and 2D- and 3D-TEE guidance (18), the device was
advanced via the transseptal route across the MV into the left
ventricle. With the 2 arms of the clip extended, the device
was retracted to capture, and subsequently closed to coapt,
the MV leaﬂets. Standard mid-esophageal 2D views are not
available for noncentral pathology. A 3D “enface” view of the
MV was mandatory for alignment of the clip in the lateral or
medial aspects of the curved line of coaptation (Fig. 1D).
Nonstandard 2D views were used to monitor the closure of
the clip arms and to verify good leaﬂet insertion (Fig. 1E). In
order to compensate for the height increment of the system
when advanced laterally in the left atrium, 5 mm was
deducted from the recommended optimal septal puncture
height for central pathology if lateral noncentral pathology
was treated and 5 mm was added if medial noncentral
pathology was treated. Retraction of the steerable guide in the
right atrium was accepted if needed to treat medial pathology.
If 2 clips were needed, it was preferred to implant the ﬁrst clip
in the most central aspect of the pathology. Resultant valve
morphologies after clip implantation in central and
noncentral pathologies are shown in Figures 1C and 1F.Table 1 Baseline Clinical Characteristics
Overall
(N ¼ 79)
Age, yrs 79.2  7.9
Male 46 (58.2)
Diabetes mellitus 7 (8.9)
Hypertension 50 (63.3)
COPD 23 (29.1)
Stroke 5 (6.3)
Previous MI 11 (13.9)
Previous PCI 9 (11.4)
Previous CABG 11 (13.9)
Previous AVR 7 (8.9)
Previous AF 43 (54.4)
NYHA functional class
II 5 (6.3)
III 66 (83.5)
IV 8 (10.2)
Logistic EuroSCORE, % 14.3  10.3
Baseline creatinine, mg/dl 1.2  0.4
Baseline hemoglobin, g/dl 12.3  1.8
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; AVR ¼ aortic valve replacement; CABG ¼ coronar
MI ¼ myocardial infarction; NYHA ¼ New York Heart Association; PCI ¼ perPatients were extubated after the procedure in the cath-
eterization laboratory and transferred to the intensive care
unit or recovery room where they were monitored until ﬁt
for ward transfer.
Post-procedural care. Anticoagulation management was
based on an individualized protocol. Patients on warfarin
continued on an identical regimen after the intervention;
in the remainder of patients, acetylsalicylic acid (75 to 150
mg/day) was prescribed for 3months and clopidogrel (75 mg/
day) for 4 weeks. Clinical and echocardiographic follow-up
was performed at discharge and 1 and 6 months post-
procedure.
Statistical analysis. Results are presented as mean  SD
for continuous normally distributed variables, as median
(interquartile range) for continuous non-normally distributed
data, and as percentages for categorical data. Analysis of
normality was performed with the Kolmogorov-Smirnov and
Shapiro-Wilk tests. Categorical data and proportions were
compared using chi-square test or Fisher exact test, as
required. Comparisons of continuous variables were analyzed
using unpaired Student t test and the Mann-Whitney U test
as appropriate. The Kaplan-Meier method was used for
survival analysis and curves. Values of p <0.05 were consid-
ered signiﬁcant. All analyses were performed with SPSS 20.0
statistical package for Windows (IBM SPSS, Chicago,
Illinois).Results
Baseline characteristics. Among the 173 consecutive
patients who received MitraClip implantation between
August 2009 and November 2012, 79 patients were foundCentral
(n ¼ 49)
Non-Central
(n ¼ 30) p Value
79.4  8.0 78.8  7.5 0.761
29 (59.2) 17 (56.7) 0.826
6 (12.2) 1 (3.3) 0.176
30 (61.2) 20 (66.7) 0.628
16 (32.7) 7 (23.3) 0.376
3 (6.1) 2 (6.7) 0.923
8 (16.3) 3 (10.0) 0.431
5 (10.2) 4 (13.3) 0.671
6 (12.2) 5 (16.7) 0.582
3 (6.1) 4 (13.3) 0.274
25 (51.0) 18 (60.0) 0.437
0.064
4 (8.2) 1 (3.3)
43 (87.8) 23 (76.7)
2 (4.0) 6 (20.0)
14.7  11.0 13.7  8.9 0.687
1.4  0.4 1.2  0.4 0.569
11.9  1.7 12.7  2.0 0.574
y artery bypass graft; COPD ¼ chronic obstructive pulmonary disease;
cutaneous coronary intervention.
Table 2 Echocardiographic Data
Pre-Clip Post-Clip (1 month)
Overall
(N ¼ 79)
Central
(n ¼ 49)
Non-Central
(n ¼ 30) p Value*
Overall
(N ¼ 79)
Central
(N ¼ 49)
Non-Central
(N ¼ 30) p Valuey
LVEDD, cm 5.3  0.7 5.3  0.8 5.3  0.7 0.949 5.0  0.6 4.9  0.6 5.1  0.6 0.372
LVESD, cm 3.4  0.8 3.4  0.9 3.3  0.8 0.585 3.5  0.8 3.4  0.7 3.5  0.8 0.425
LVEDV, ml 119.6  50.0 115.9  46 124.5  55.7 0.538 108.0  41.4 109.8  44.0 105.8  39.0 0.749
LVESV, ml 55.8  36.7 59.1  36 58.5  37.2 0.766 54.8  31.9 53.9  33.3 56  30.8 0.829
LVEF, % 58.6  10.5 58.9  11 58  9.7 0.716 55.0  9.5 56.0  9.5 53.3  9.6 0.255
MR quantiﬁcation
EROA, cm2 0.54  0.3 0.52  0.3 0.57  0.4 0.610 d d d d
VC, mm 7.4  2.2 6.9  2.2 8.5  2 0.039 d d d d
RV, ml 74.2  39.7 74.4  38 73.7  43 0.960 d d d d
Baseline mean mitral
gradient, mm Hg
2.1  1.0 2.0  0.8 2.3  1.2 0.284 3.0  2.2 3.1  2.3 2.8  2.0 0.568
Systolic pulmonary
pressure, mm Hg
51.3  15.7 47.3  13 57.9  18 0.019 43.8  11.1 42.5  10.0 46  11.2 0.238
Values are mean  SD. *Central versus noncentral pre-clip. yCentral versus noncentral post-clip.
EROA ¼ effective regurgitant oriﬁce area; LVEDD ¼ left ventricular end-diastolic diameter; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESD ¼ left ventricular
end-systolic diameter; LVESV ¼ left ventricular end-systolic volume; MR ¼ mitral regurgitation; RV ¼ regurgitant volume; VC ¼ vena contracta.
JACC Vol. 62, No. 25, 2013 Estévez-Loureiro et al.
December 24, 2013:2370–7 The MitraClip for Noncentral Mitral Regurgitation
2373to have dMR. Of these, 49 (62%) had central dMR. The
remainder were classiﬁed as noncentral dMR (n ¼ 30, 38%
[23 patients A3/P3 and 7 patients A1/P1]). Baseline char-
acteristics of both groups were similar (Table 1).
Most patients were in NYHA functional class III or IV
(noncentral 96.7% vs. central 91.8%, p ¼ 0.644). There was
a trend towards a greater severity in the quantitative
parameters of MR in the noncentral group that reached
signiﬁcance with regard to the vena contracta. Systolic
pulmonary pressure was signiﬁcantly higher in the noncen-
tral group (Table 2). The proportion of patients undergoing
MitraClip implantations in noncentral positions has
increased over time (Fig. 2).
Procedural outcome. Procedural success was obtained in 76
patients (96.2%), with no signiﬁcant differences between
central (n ¼ 47, 95.5%) and noncentral dMR (n ¼ 29,Figure 2
Annual Increase of MitraClip Implantation in
Noncentral MR
There is a progressive increment with time, related to increasing experience.
MR ¼ mitral regurgitation.96.7%, p ¼ 0.866). We found no signiﬁcant differences in
the procedural time, although noncentral patients had
slightly longer procedures (central 107.8  61.5 min vs.
noncentral 123.6  63.2 min, p ¼ 0.505). There was no
signiﬁcant difference in the number of implanted clips
between groups, although numerically more patients with
noncentral dMR received more than 1 clip (53.3% vs.
40.8%, p ¼ 0.278). The number of complications (n ¼ 10,
12.6%) was not signiﬁcantly different between groups
(Table 3).
There were no cases of prolonged clip entanglement, clip
embolization, or septal complications. Two patients expe-
rienced gastrointestinal bleeding requiring transfusions (1 in
each group). One patient with central dMR developed
cardiac tamponade after the procedure that was successfully
drained by pericardiocentesis. One patient needed temporary
pacemaker implantation due to transient heart block (central
group). Another patient developed pneumonia during
admission that was successfully treated with antibiotics.
One patient in the central group underwent elective MV
surgery <30 days after the procedure due to severe MR. One
patient (1.2%) died <30 days after the procedure (noncen-
tral group, 81 years old, ejection fraction 25%, chronic
kidney disease, logistic EuroSCORE 52.8%) due to
complications of comorbidities.
Post-MitraClip echocardiographic evaluation: effect onMR.
We observed a reduction in MR severity in all patients, with
most of the patients having MR 2. There was no difference
in the extent of reduction of MR between the central and
noncentral groups (Fig. 3). The reduction in MR severity was
sustained in both groups at 6 months (Fig. 3), with nonsig-
niﬁcant differences in the proportion of patients with MR
>2 (4.8% central vs. 8.3% noncentral, p ¼ 0.679).
At 1 month, there was overall a positive effect of the
treatment with regard to LV dimensions and volumes; the
ejection fraction was lower than before intervention. There
Table 3 Periprocedural Adverse Events
Overall
(N ¼ 79)
Central
(n ¼ 49)
Non-Central
(n ¼ 30) p Value
Clip embolization 0 (0) 0 (0) 0 (0) d
Partial clip
detachment
2 (2.5) 1 (2) 1 (3.3) 1.000
Prolonged clip
entanglement
0 (0) 0 (0) 0 (0) 1.000
Chordal rupture 1 (1.2) 1 (2) 0 (0) 1.000
Cardiac tamponade 1 (1.2) 1 (2) 0 (0) 1.000
Gastro-intestinal
bleeding
2 (2.5) 1 (2) 1 (3.3) 1.000
Stroke 0 (0) 0 (0) 0 (0) d
Transient AV block 1 (1.2) 1 (2) 0 (0) 1.000
Pneumonia 1 (1.2) 1 (2) 0 (0) 1.000
Mitral valve surgery 1 (1.2) 1 (2) 0 (0) 1.000
Death 1 (1.2) 0 (0) 1 (3.3) 1.000
All complications 10 (12.6) 7 (14.3) 3 (10) 0.734
Values are n (%).
AV ¼ atrioventricular.
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2374were no differences between the central and noncentral
groups with regard to changes of LV parameters (Table 2).
There was a signiﬁcant increase of the mean transmitral
gradient (p < 0.001) and decrease in the systolic pulmonary
pressure (p < 0.001) 1 month after the procedure. There
were no differences between the central and noncentral
groups with regard to these 2 parameters. At 1 month,
24.8% of patients had a mean post-procedural transmitral
gradient 5 mm Hg, without signiﬁcant differences
between the central and noncentral groups (26.5% central
vs. 20% noncentral, p ¼ 0.510).Figure 3 MR Grade at Baseline, 1 Month, and 6 Months Following M
Pre- and post-intervention mitral regurgitation (MR) in all patients (A). MR grade at 1-mon
proportion of patients with MR grade 0 to 1 in the noncentral group. However, there was no
ﬁgure is for the overall comparison across categories).Clinical outcomes. At 1 month, NYHA functional class
had improved (p < 0.001), with no differences between the
central and noncentral MR groups (Fig. 4). There were also
no signiﬁcant differences at 6-month follow-up, although
the proportion of patients with NYHA functional class >II
was higher in the central group (21.1% vs. 0%, p ¼ 0.128, 32
patients).
Data regarding all-cause mortality (8.3%) and re-
admission due to heart failure (10%) were available in 60
patients (37 patients central and 23 patients noncentral,
follow-up 15.2  11.0 months). There were no differences
between the central and noncentral groups with regard to
mortality (n ¼ 2 [5.4%] central vs. n ¼ 3 [13.0%]
noncentral, p ¼ 0.298) and hospital re-admission (n ¼ 4
[10.8%] central vs. n ¼ 2 [8.7%] noncentral, p ¼ 0.791).
There were no signiﬁcant differences between the groups
with regard to death and readmission (log-rank p ¼ 0.506).
Survival curves are shown in Figure 5.Discussion
This study analyzed the results of 3 experienced centers
using percutaneous edge-to-edge MV repair. Our results
show for the ﬁrst time to our knowledge the feasibility of
treating noncentral dMR with the MitraClip. Reduction of
MR, LV remodeling, and clinical events was comparable in
central and noncentral dMR.
There has been an increasing interest in extending the use
of the MitraClip system to patients that do not meet the
inclusion criteria of the EVEREST trials (9–11). GooditraClip Intervention
th post-procedure in both groups (B) and MR at 6 months (C). There was a higher
difference between groups with regard to the proportion of MR 2 (the p value in the
Figure 4 Distribution of NYHA Functional Class at Baseline, Post-Procedure, and at 1-Month and 6-Month Follow-Up
A signiﬁcant improvement in functional class at 1 month was observed after MitraClip intervention (A). At 1 month, there is no difference between groups with regard to
functional class improvement (B). However, at 6-month follow-up, more patients in the noncentral group were in New York Heart Association (NYHA) functional class II,
although this difference was not statistically signiﬁcant (C). (The p value in the ﬁgure is for the overall comparison across categories.)
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2375results in patients not amenable for surgery (19) have been
reported, with a procedural success of 92% and 83% of the
patients having MR 2þ at a median follow-up of 1 year.
The mortality at 1 year was 25%. In patients with end-stage
heart failure, similar results have been observed (13), with
a procedural success of 94% and 87% of the patients having
MR 2þ at 6 months. The mortality at 6 months was 16%.Figure 5
Kaplan-Meier Survival Curves of Freedom From
Death or Re-Admission due to Heart Failure
There is no signiﬁcant difference between groups. Chi-sq ¼ chi-square test;
Cum ¼ cumulative.The MitraClip has been shown to be an acceptable alter-
native in nonsurgical patients (20). However, these studies
have demonstrated the beneﬁt of percutaneous repair in
a certain subset of clinical proﬁles, but none of them have
focused on noncentral MV pathology. In a recent article by
George et al. (21), commenting on the results from the
EVEREST II trial, it was stressed that the MitraClip would
only be suitable for a selected subgroup of patients with
central MR. In opposition to this, it has been suggested
that in a real-world population with wider valve suitability
criteria, results of the MitraClip therapy can be comparable
to the EVEREST experience (12).
Medically treated patients with severe dMR have a 6%
annual mortality rate (22). Surgical noncentral repair is
considered more challenging and has been shown to be
associated with increased risk for reoperation and MV
replacement (23,24). Consequently, MitraClip therapy
for MR jets originating from the medial or lateral aspect of
the line of coaptation may also be more challenging and
less safe. There is a chordae-free zone in the central part of
the anterior leaﬂet. The structure of the chordae tendineae
in the commissural areas is more complex (Fig. 6) and the
anatomical orientation in 2D echocardiography is more
difﬁcult in the noncentral area. This may impose a higher
risk for clip entanglement.
Our results show that the MitraClip can be safely
implanted in a noncentral position of the MV, with a
procedural success rate similar to central positioning.
Noncentral implantation was associated with a sustained
MR reduction, LV remodeling, and clinical improvement
Figure 6 Anatomic Specimen of Mitral Valve Depicting Structure of Chordae Tendineae
(A) This panel shows the chordae-free zone of the anterior mitral leaﬂet. (B) Fan-shaped chordae in the medial commissure are shown.
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2376during follow-up, similar to previous reports of high-risk
patients (12,19,20). There was no difference in the rates of
mortality or readmission for heart failure between the groups
with a risk proﬁle comparable to other series (19).
These ﬁndings challenge the concept that noncentral
positioning of a MitraClip is associated with worse clinical
outcome because of interference with the subvalvular
apparatus (25,26). There was no prolonged clip entangle-
ment in the noncentral group. It suggests that the indica-
tion for MitraClip implantation may be expanded to
noncentral dMR. However, certain practical issues should
be considered with respect to noncentral dMR in this
study. First, all patients underwent 3D-TEE study before
the procedure because accurate valve analysis is key for
successful mitral repair (27,28). In noncentral pathology,
intraprocedural 3D-TEE was felt to be essential for correct
clip orientation. Procedural changes must be considered in
regard to septal puncture, guide catheter positioning, and
grasping. Additionally, it needs to be stressed that the rate
of noncentral MitraClip placement is increasing over time.
This probably reﬂects a “learning curve” effect and
a tendency to accept more challenging valve anatomy with
growing experience.
Study limitations. The study is small in size, and
a considerable number of patients were not available for
follow-up at 6 months. Our results are the compilation of
data from highly experienced centers and operators. MR
grading is self-reported without use of a core laboratory.
Conclusions
MitraClip treatment of noncentral dMR is safe and asso-
ciated with similar short-term and mid-term outcomes as
the treatment of central MR. Our ﬁndings suggest that the
valve suitability criteria for MitraClip therapy can be
expanded to patients with noncentral origin of MR.Acknowledgment
The authors thank Michael Schlueter, PhD, for his valuable
comments and corrections.
Reprint requests and correspondence: Dr. Olaf Franzen,
Department of Cardiology, Rigshospitalet Copenhagen, Blegdams-
vej 9, 2100 Copenhagen, Denmark. E-mail: owfranzen@gmx.de.REFERENCES
1. Rosen SE, Borer JS, Hochreiter C, et al. Natural history of the
asymptomatic/minimally symptomatic patient with severe mitral
regurgitation secondary to mitral valve prolapse and normal right and
left ventricular performance. Am J Cardiol 1994;74:374–80.
2. Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of
mitral regurgitation due to ﬂail leaﬂet. N Engl J Med 1996;335:
1417–23.
3. Trichon BH, Felker GM, Shaw LK, Cabell CH, O’Connor CM.
Relation of frequency and severity of mitral regurgitation to survival
among patients with left ventricular systolic dysfunction and heart
failure. Am J Cardiol 2003;91:538–43.
4. Agricola E, Ielasi A, Oppizzi M, et al. Long-term prognosis of
medically treated patients with functional mitral regurgitation and left
ventricular dysfunction. Eur J Heart Fail 2009;11:581–7.
5. Vahanian A, Alﬁeri O, Andreotti F, et al. Guidelines on the
management of valvular heart disease (version 2012). Eur Heart J 2012;
33:2451–96.
6. Mirabel M, Iung B, Baron G, et al. What are the characteristics of
patients with severe, symptomatic, mitral regurgitation who are denied
surgery? Eur Heart J 2007;28:1358–65.
7. Borger MA, Alam A, Murphy PM, Doenst T, David TE. Chronic
ischemic mitral regurgitation: repair, replace or rethink? Ann Thorac
Surg 2006;81:1153–61.
8. Jamieson WR, Edwards FH, Schwartz M, Bero JW, Clark RE,
Grover FL. Risk stratiﬁcation for cardiac valve replacement. National
Cardiac Surgery Database. Database Committee of The Society of
Thoracic Surgeons. Ann Thorac Surg 1999;67:943–51.
9. Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous
mitral valve repair using the edge-to-edge technique: six-month results
of the EVEREST phase I clinical trial. J Am Coll Cardiol 2005;46:
2134–40.
10. Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the
MitraClip system: safety and midterm durability in the initial
JACC Vol. 62, No. 25, 2013 Estévez-Loureiro et al.
December 24, 2013:2370–7 The MitraClip for Noncentral Mitral Regurgitation
2377EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort.
J Am Coll Cardiol 2009;54:686–94.
11. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery
for mitral regurgitation. N Engl J Med 2011;364:1395–406.
12. Franzen O, Baldus S, Rudolph V, et al. Acute outcomes of MitraClip
therapy for mitral regurgitation in high-surgical-risk patients: emphasis
on adverse valve morphology and severe left ventricular dysfunction.
Eur Heart J 2010;31:1373–81.
13. Franzen O, van der Heyden J, Baldus S, et al. MitraClip therapy in
patients with end-stage systolic heart failure. Eur J Heart Fail 2011;13:
569–76.
14. Auricchio A, Schillinger W, Meyer S, et al. Correction of mitral
regurgitation in nonresponders to cardiac resynchronization therapy by
MitraClip improves symptoms and promotes reverse remodeling. J Am
Coll Cardiol 2011;58:2183–9.
15. Lancellotti P, Moura L, Pierard LA, et al. European Association of
Echocardiography recommendations for the assessment of valvular
regurgitation. Part 2: mitral and tricuspid regurgitation (native valve
disease). Eur J Echocardiogr 2010;11:307–32.
16. Zamorano JL, Badano LP, Bruce C, et al. EAE/ASE recommenda-
tions for the use of echocardiography in new transcatheter interventions
for valvular heart disease. Eur Heart J 2011;32:2189–214.
17. Lang RM, Bierig M, Devereux RB, et al. Recommendations for
chamber quantiﬁcation: a report from the American Society of Echo-
cardiography’s Guidelines and Standards Committee and the Chamber
Quantiﬁcation Writing Group, developed in conjunction with the
European Association of Echocardiography, a branch of the European
Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440–63.
18. Silvestry FE, Rodriguez LL, Herrmann HC, et al. Echocardiographic
guidance and assessment of percutaneous repair for mitral regurgitation
with the Evalve MitraClip: lessons learned from EVEREST I. J Am
Soc Echocardiogr 2007;20:1131–40.
19. Rudolph V, Knap M, Franzen O, et al. Echocardiographic and clinical
outcomes of MitraClip therapy in patients not amenable to surgery.
J Am Coll Cardiol 2011;58:2190–5.20. Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month
results with catheter-based mitral valve leaﬂet repair: the EVEREST II
(Endovascular Valve Edge-to-Edge Repair) high risk study. J Am Coll
Cardiol 2012;59:130–9.
21. George JC, Varghese V, Dangas G, Feldman TE. Percutaneous
mitral valve repair: lessons from the EVEREST II (Endovascular
Valve Edge-to-Edge REpair Study) and beyond. J Am Coll Cardiol
Intv 2011;4:825–7.
22. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation.
Lancet 2009;373:1382–94.
23. Aubert S, Barreda T, Acar C, et al. Mitral valve repair for commissural
prolapse: surgical techniques and long term results. Eur J Cardiothorac
Surg 2005;28:443–7.
24. Barabas M, Cormier B, Iung B, et al. Commissural lesions causing
severe mitral regurgitation: a marker of severity for valve repair. Eur
Heart J 1997;Abstr Suppl:247.
25. Van Mieghem NM, Piazza N, Anderson RH, et al. Anatomy of the
mitral valvular complex and its implications for transcatheter inter-
ventions for mitral regurgitation. J Am Coll Cardiol 2010;56:
617–26.
26. Rogers JH, Franzen O. Percutaneous edge-to-edge MitraClip therapy
in the management of mitral regurgitation. Eur Heart J 2011;32:
2350–7.
27. Biaggi P, Jedrzkiewicz S, Gruner C, et al. Quantiﬁcation of mitral
valve anatomy by three-dimensional transesophageal echocardiog-
raphy in mitral valve prolapse predicts surgical anatomy and the
complexity of mitral valve repair. J Am Soc Echocardiogr 2012;25:
758–65.
28. Ciobanu A, Bennett S, Azam M, Clark A, Vinereanu D. Incremental
value of three-dimensional transoesophageal echocardiography for
guiding double percutaneous MitraClip  implantation in a ‘no option’
patient. Eur J Echocardiogr 2011;12:E11.Key Words: catheter-based-therapy - heart valves - mitral regurgitation.
